Measurement of residual radioactivity in postoperative inpatients with differentiated thyroid carcinoma after 131I treatment using robot

中华核医学与分子影像杂志 Pub Date : 2019-10-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.10.006

Q. Ji, R. Di, Weina Chen, Jing Pan, Yang Liu, Hui Shang, Gege Kong, Yaoshan Ye, Bing Cheng, Xiangzhou Li, Xin Wen, Xingmin Han

{"title":"Measurement of residual radioactivity in postoperative inpatients with differentiated thyroid carcinoma after 131I treatment using robot","authors":"Q. Ji, R. Di, Weina Chen, Jing Pan, Yang Liu, Hui Shang, Gege Kong, Yaoshan Ye, Bing Cheng, Xiangzhou Li, Xin Wen, Xingmin Han","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.10.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the residual radioactivity after 131I treatment in postoperative inpatients with differentiated thyroid carcinoma (DTC) using service robot in nuclear medicine ward, and assess the time for patients to be released from isolation. \n \n \nMethods \nFrom September 2017 to June 2018, 297 patients (94 males, 203 females, age: 19-80 years) with DTC who underwent 131I treatment after surgery were included. According to the purpose of treatment and the prescription dosage of 131I, patients were divided into 8 groups: 4 groups accepted 131I remnant ablation therapy (RAT) with different dosages, which were 3 700 MBq (RAT1, n=34), 4 440 MBq (RAT2, n=122), 5 550 MBq (RAT3, n=81) and 7 400 MBq (RAT4, n=27), respectively; 4 groups had 131I treatment for recurrent/metastatic lesions (RMLT), and the dosages were 3 700 MBq (n=1), 4 440 MBq (n=2), 5 550 MBq (n=14) and 7 400 MBq (n=16). At 4, 24, 48 and 72 h after 131I administration, the dose equivalent rates at 2 cm away from the patient′s neck and at 1 m away from the body were measured by the robot designed for nuclear medicine ward. Kruskal-Wallis rank sum test and Mann-Whitney U test were used to analyze the data. \n \n \nResults \nNeck dose equivalent rates for patients with RAT at different time points (4, 24, 48 and 72 h) after 131I administration were significantly different among 4 groups (H values: 20.889-46.410, all P 0.05). The radioactivity retention in patients decreased rapidly within 24 h, then slowed down gradually and became extremely low at 72 h. At 72 h after 131I administration, 96.6%(255/264) patients with RAT and 100%(33/33) patients with RMLT were lower than 23.3 μSv/h, which meant the patients could be discharged from hospitalization. \n \n \nConclusions \nNuclear medicine ward service robots may dynamically measure residual radioactivity in DTC patients who take 131I treatment, providing individualized isolation solutions. \n \n \nKey words: \nThyroid neoplasms; Radiotherapy; Iodine radioisotopes; Drug residues; Radiation dosage; Robotics","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"601-605"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.10.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To evaluate the residual radioactivity after 131I treatment in postoperative inpatients with differentiated thyroid carcinoma (DTC) using service robot in nuclear medicine ward, and assess the time for patients to be released from isolation. Methods From September 2017 to June 2018, 297 patients (94 males, 203 females, age: 19-80 years) with DTC who underwent 131I treatment after surgery were included. According to the purpose of treatment and the prescription dosage of 131I, patients were divided into 8 groups: 4 groups accepted 131I remnant ablation therapy (RAT) with different dosages, which were 3 700 MBq (RAT1, n=34), 4 440 MBq (RAT2, n=122), 5 550 MBq (RAT3, n=81) and 7 400 MBq (RAT4, n=27), respectively; 4 groups had 131I treatment for recurrent/metastatic lesions (RMLT), and the dosages were 3 700 MBq (n=1), 4 440 MBq (n=2), 5 550 MBq (n=14) and 7 400 MBq (n=16). At 4, 24, 48 and 72 h after 131I administration, the dose equivalent rates at 2 cm away from the patient′s neck and at 1 m away from the body were measured by the robot designed for nuclear medicine ward. Kruskal-Wallis rank sum test and Mann-Whitney U test were used to analyze the data. Results Neck dose equivalent rates for patients with RAT at different time points (4, 24, 48 and 72 h) after 131I administration were significantly different among 4 groups (H values: 20.889-46.410, all P 0.05). The radioactivity retention in patients decreased rapidly within 24 h, then slowed down gradually and became extremely low at 72 h. At 72 h after 131I administration, 96.6%(255/264) patients with RAT and 100%(33/33) patients with RMLT were lower than 23.3 μSv/h, which meant the patients could be discharged from hospitalization. Conclusions Nuclear medicine ward service robots may dynamically measure residual radioactivity in DTC patients who take 131I treatment, providing individualized isolation solutions. Key words: Thyroid neoplasms; Radiotherapy; Iodine radioisotopes; Drug residues; Radiation dosage; Robotics

查看原文本刊更多论文

应用机器人测量分化型甲状腺癌131I治疗后住院患者的残余放射性

目的利用核医学病房服务机器人对分化型甲状腺癌（DTC）术后住院患者131I治疗后的放射性残留进行评估，并评估患者解除隔离的时间。方法自2017年9月至2018年6月，297名DTC患者（94名男性，203名女性，年龄：19-80岁）在手术后接受131I治疗。根据治疗目的和131I的处方剂量，将患者分为8组：4组接受不同剂量的131I残余消融治疗（RAT），分别为3700MBq（RAT1，n=34）、440MBq（RAT2，n=122）、5.550MBq（RAT3，n=81）和7400MBq（RAT4，n=27）；4组接受131I治疗复发/转移性病变（RMLT），剂量分别为3700MBq（n=1）、440MBq（n=2）、550MBq（n=14）和7400MBq（n=16）。在131I给药后4、24、48和72小时，用核医学病房设计的机器人测量患者颈部2cm和身体1m处的剂量当量率。使用Kruskal-Wallis秩和检验和Mann-Whitney U检验对数据进行分析。结果4组大鼠131I给药后不同时间点（4、24、48和72 h）的颈部剂量当量率差异有统计学意义（h值：20.889-46.410，均P＜0.05），96.6%（255/264）的RAT患者和100%（33/33）的RMLT患者低于23.3μSv/h，这意味着患者可以出院。结论核医学病房服务机器人可以动态测量接受131I治疗的DTC患者的残余放射性，提供个性化的隔离解决方案。关键词：甲状腺肿瘤；放射治疗；碘放射性同位素；药物残留；辐射剂量；机器人

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.